Stockholders’ Equity (Details) $ / shares in Units, $ in Thousands					3 Months Ended	9 Months Ended
	Jan. 08, 2025 shares	Dec. 11, 2024 USD ($)	Dec. 09, 2024 $ / shares shares	Apr. 05, 2024 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Dec. 31, 2024 $ / shares shares
Stockholders’ Equity [Line Items]
Common stock, shares authorized					100,000,000	100,000,000	100,000,000
Common stock, par value (in Dollars per share) \| $ / shares					$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued					38,587,260	38,587,260	35,044,772
Common stock, shares outstanding					38,587,260	38,587,260	35,044,772
Preferred stock, shares authorized					10,000,000	10,000,000	10,000,000
Preferred stock, par value (in Dollars per share) \| $ / shares					$ 0.001	$ 0.001	$ 0.001
Preferred stock convertible conversion ratio							1,000
Preferred stock, liquidation preference per share (in Dollars per share) \| $ / shares							$ 7.01
Warrants exercised
April 2024 Common Warrants [Member]
Stockholders’ Equity [Line Items]
Purchase of warrant				10,843,380
Purchase price per share (in Dollars per share) \| $ / shares				$ 4.15
Exercise price per share (in Dollars per share) \| $ / shares					$ 5.25	$ 5.25
Warrants, outstanding					10,118,380	10,118,380
Warrants exercised
April Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Purchase price per share (in Dollars per share) \| $ / shares				$ 4.149
Exercise price per share (in Dollars per share) \| $ / shares					$ 0.001	$ 0.001
Minimum rate of percentage						42.00%
Pre-funded warrants are outstanding						1,700,000
Pre-funded warrant exercised
December 2024 Pre-Funded Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares			$ 6.249
Pre-funded warrants are outstanding						1,700,272
Pre-funded warrant exercised					0	625,100
Series 1 Convertible Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock, shares authorized					8,028	8,028	8,028
Preferred stock, shares issued					5,615	5,615	7,991
Preferred stock, shares outstanding					5,615	5,615	7,991
Preferred stock convertible conversion ratio					1,000	1,000
Preferred stock, liquidation preference per share (in Dollars per share) \| $ / shares					$ 7.01	$ 7.01
Shares of convertible preferred stock converted					0	2,376
Common shares issued upon conversion of convertible preferred stock						2,376,244
April 2024 Private Placement [Member]
Stockholders’ Equity [Line Items]
Stock issued in private placement				9,143,380
Pre funded warrants purchased shares				1,700,000
Gross proceeds from private placement (in Dollars) \| $				$ 44,998
Net proceeds from private placement (in Dollars) \| $				41,964
Private placement, net of offering costs (in Dollars) \| $				$ 3,034
Common stock beneficially owned percentage limit for april warrant holders.						9.99%
Beneficially owned percentage						19.99%
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, par value (in Dollars per share) \| $ / shares					$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued					38,587,260	38,587,260
Number of vote per share						one
April 2024 Pre-Funded Warrant or Common Warrant [Member] \| April 2024 Private Placement [Member]
Stockholders’ Equity [Line Items]
Beneficially owned percentage						4.99%
April 2024 Private Placement [Member]
Stockholders’ Equity [Line Items]
Additional terms of agreement, description.					Both the April 2024 Pre-Funded Warrants and the April 2024 Common Warrants contain standard adjustments to the exercise price, inclusive of stock splits, stock dividends and pro rata distributions and contain customary terms regarding the treatment of such April 2024 Pre-Funded Warrants or April 2024 Common Warrants in the event of a fundamental transaction, which include but are not limited to a merger or consolidation involving the Company, a sale of all or substantially all of the assets of the Company or a business combination resulting in any person acquiring more than 50% of the outstanding shares of common stock of the Company.	Both the April 2024 Pre-Funded Warrants and the April 2024 Common Warrants contain standard adjustments to the exercise price, inclusive of stock splits, stock dividends and pro rata distributions and contain customary terms regarding the treatment of such April 2024 Pre-Funded Warrants or April 2024 Common Warrants in the event of a fundamental transaction, which include but are not limited to a merger or consolidation involving the Company, a sale of all or substantially all of the assets of the Company or a business combination resulting in any person acquiring more than 50% of the outstanding shares of common stock of the Company.
December 2024 Public Offering [Member]
Stockholders’ Equity [Line Items]
Common stock, par value (in Dollars per share) \| $ / shares			$ 0.001
Shares issued in underwritten public offering			13,690,000
Price per share (in Dollars per share) \| $ / shares			$ 6.25
Gross proceeds (in Dollars) \| $		$ 100,100
Net proceeds (in Dollars) \| $		93,400
Public offering costs (in Dollars) \| $		$ 6,700
December 2024 Public Offering [Member] \| Underwriters Option [Member]
Stockholders’ Equity [Line Items]
Purchase an additional share			2,402,305
Gross proceeds (in Dollars) \| $					$ 2,700	$ 2,700
Additional shares issued	438,738
Net proceeds (in Dollars) \| $					2,500	2,500
Underwriters’ fees, legal costs and other expenses (in Dollars) \| $					$ 200	$ 200
December 2024 Pre-Funded Warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrants purchased shares			2,325,372
Exercise price per share (in Dollars per share) \| $ / shares			$ 0.001		$ 0.001	$ 0.001
Beneficially owned percentage						4.99%
December 2024 Public Offering [Member]
Stockholders’ Equity [Line Items]
Additional terms of agreement, description.					The December 2024 Pre-Funded Warrants contain standard adjustments to the exercise price, including for stock splits, stock dividends and pro rata distributions and contain customary terms regarding the treatment of such December 2024 Pre-Funded Warrants in the event of a fundamental transaction, which include but are not limited to a merger or consolidation involving the Company, a sale of all or substantially all of the assets of the Company or a business combination resulting in any person acquiring more than 50% of the outstanding shares of common stock of the Company.	The December 2024 Pre-Funded Warrants contain standard adjustments to the exercise price, including for stock splits, stock dividends and pro rata distributions and contain customary terms regarding the treatment of such December 2024 Pre-Funded Warrants in the event of a fundamental transaction, which include but are not limited to a merger or consolidation involving the Company, a sale of all or substantially all of the assets of the Company or a business combination resulting in any person acquiring more than 50% of the outstanding shares of common stock of the Company.

Protara Therapeutics, Inc. 10-Q